![](https://webarchive.library.unt.edu/web/20090509204216im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/web/20090509204216im_/http://www.cancer.gov/images/spacer.gif)
c-Met inhibitor ARQ 197 An orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity. c-Met inhibitor ARQ 197 binds to the c-Met protein and disrupts c-Met signal transduction pathways, which may induce cell death in tumor cells overexpressing c-Met protein or expressing consitutively activated c-Met protein. c-Met protein, the product of the proto-oncogene c-Met, is a receptor tyrosine kinase also known as hepatocyte growth factor receptor (HGFR); this protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/web/20090509204216im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/web/20090509204216im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/web/20090509204216im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/web/20090509204216im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/web/20090509204216im_/http://www.cancer.gov/images/spacer.gif) |